ТЕРАПИЯ ИМПЛАНТИРУЕМЫХ КАРДИОВЕРТЕРОВ-ДЕФИБРИЛЛЯТОРОВ НА СОВРЕМЕННОМ ЭТАПЕ: СОВЕРШЕНСТВОВАНИЕ И СТАНДАРТИЗАЦИЯ МЕТОДА
Аннотация
Рассматривается применение имплантируемых кардиовертеров-дефибрилляторов для первичной и вторичной профилактики внезапной сердечной смерти, обсуждаются роль антитахикардитической терапии, проблема необоснованных разрядов, методы снижения их количества.
Об авторах
А. Ш. Ревишвили
ФГБУ «Институт хирургии имени А.В. Вишневского»
Россия
Россия
Н. М. Неминущий
ФГБОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России
Россия
Россия
Список литературы
1. Domanski M.J., Saksena S., Epstein A.E. et al. Relative effectiveness of the implantable cardioverter defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiar-rhythmics Versus Implantable Defibrillators // J.Am.Coll. Cardiol. - 1999.-Vol. 34. - P. 1090-1095.
2. Siebels J., Kuck K.H. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivos (the Cardiac Arrest Study Hamburg) // Am. Heart.J. - 1994. - Vol. 127. - P. 1139-1144.
3. Conolly S.J., Gent M., Roberts R.S. et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amioda-rone // Circulation. - 2000. - Vol. 101. - P. 1297-1302.
4. Moss A.J., Hall W.J., Cannom D.S. et al. Improved sur vival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia // N. Engl. J. Med.- 1996.- N. 335.- P. 1933-1940.
5. Buxton A.E., Lee K.L., Di Carlo L. et al. Electrophysi-ological testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators // N. Engl.J. Med. - 2000. - Vol. 342. - № 26. - P. 1937-1945.
6. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction // N. Eng. J. Med. - 2002. - N. 346.- P. 877-883.
7. Bardy G.H, Lee K.L, Mark D.B, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure // N. Engl.J.Med. - 2005. - Vol. 352. - P.225-237.
8. Daubert JP, Zareba W, Cannom DS, et al, for the MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. April 8, 2008; 51(14): 1357-1365. ВЕСТНИК АРИТМОЛОГИИ, № 87, 2017
9. Kadish A., Dyer A., Daubert J.P., et al, for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. May 20, 2004; 350(21): 2151-2158.
10. Poole J.E., Johnson G.W., Hellkamp A.S., et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. September 4, 2008; 359(10): 1009-1017.
11. Mitka M. New study supports lifesaving benefits of implantable defibrillation devices. JAMA. July 8, 2009; 302(2): 134-135.
12. Sears, S.E. Jr., Conti, J.B. Understanding implantable cardioverter defibrillator shocks and storms: medical and psychosocial considerations for research and clinical care. Clin Cardiol. 2003; 26: 107-111.
13. Kuhl, E.A., Dixit, N.K., Walker, R.L. et al, Measurement of patient fears about implantable cardioverter defibrillator shock: an initial evaluation of the Florida Shock Anxiety Scale. Pacing Clin Electrophysiol. 2006; 29: 614-618.
14. Kamphuis, H.C., de Leeuw, J.R., Derksen, R. et al, Implantable cardioverter defibrillator recipients: quality of life in recipients with and without ICD shock delivery: a prospective study. Europace. 2003; 5: 381-389.
15. Irvine, J., Dorian, P., Baker, B. et al, Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J. 2002; 144: 282-289.
16. Sola, C.L., Bostwick, J.M. Implantable cardioverter-defibrillators, induced anxiety, and quality of life. Mayo Clin Proc. 2005; 80: 232-237.
17. DeMaso, D.R., Lauretti, A., Spieth, L. et al, Psychosocial factors and quality of life in children and adolescents with implantable cardioverter-defibrillators. Am J Cardiol. 2004; 93: 582-587.
18. Crossmann, A., Pauli, P., Dengler, W. et al, Stability and cause of anxiety in patients with an implantable cardioverter-defibrillator: a longitudinal two-year follow-up. Heart Lung. 2007; 36: 87-95.
19. Bilge, A.K., Ozben, B., Demircan, S. et al, Depression and anxiety status of patients with implantable cardioverter defibrillator and precipitating factors. Pacing Clin Electrophysiol. 2006; 29: 619-626.
20. Thomas, S.A., Friedmann, E., Kao, C.W. et al, Quality of life and psychological status of patients with implantable cardioverter defibrillators. Am J Crit Care. 2006; 15: 389-398.
21. Stoddard M.F., Labovitz A.J., Stevens L.L., et al. Effects of electrophysiologic studies resulting in electrical countershock or burst pacing on left ventricular systolic and diastolic function. Am Heart J 1988; 116: 364-370
22. Sweeney M.O., Sherfesee L., DeGroot P.J. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defi-brillator patients. Heart Rhythm. 2010; 7: 353-360.
23. Moss A., Greenberg H., Case R., et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004; 110: 3760 -65.
24. Fischer A., Silver M., Sterns L. et al. Underutilization of Remote Monitoring Systems After Receiving an Implantable Cardioverter Defibrillator Shock: Data From the Shock-Less Trial. J Am Coll Cardiol. 2012; 59; 13; 1245510.
25. Borne R.T., Varosy P.D., Masoudi F.A. Implantable Cardioverter-Defibrillator Shocks. Epidemiology, Outcomes, and Therapeutic Approaches JAMA Intern Med. 2013; 173(10): 859-865.
26. Rauwolf T., Guenther M., Hass N. Ventricular oversensing in 518 patients with implanted cardiac defibrillators: incidence, complications, and solutions. Europace (2007) 9, 1041-1047.
27. Hsu S.S., Mohib S., Schroeder A., et al. T-wave oversensing in implantable cardioverter defibrillators. J Interventional Cardiac Electrophysiology. 2004; 11: 67-72.
28. Swerdlow C.D., Friedman P.A. Advanced ICD troubleshooting: Part I. Pacing Clin Electrophysiol. 2005; 28: 1322-1346.
29. Kapa S., Curwin J.H., Coyne R.F., Winters S.L. Inappropriate Defibrillator Shocks from Depolarization - Repolarization Mismatch in a Patient with Hypertrophy Cardiomyopathy Pacing Clin Electrophysiol. 2007; 30: 1408-1411.
30. Kowalski M., Ellenbogen K.A., Wood M.A., Friedman P.L. Implantable cardiac defibrillator lead failure or myo-potential oversensing? An approach to the diagnosis of noise on lead electrograms. Europace 2008; 10: 914-917.
31. Santos KR, Adragao P, Cavaco D et al. Diaphragmatic myopotential oversensing in pacemaker-dependent patients with CRT-D devices. Europace 2008; 10: 1381-1386.
32. Kleemann T., Becker T., Doenges K. et al. Annual Rate of Transvenous Defibrillation Lead Defects in Implantable Cardioverter-Defibrillators Over a Period of >10 Years Circulation 2007; 115; 2474-2480.
33. Koneru J.N., Kaszala K., Huizar J.F. et al. Lead Fracture: Incidence, Diagnosis and Preventing Inappropriate ICD Therapy. Card. Electrophysiol. Clin. 3 2011; 409-420.
34. Swerdlow C.D., Gunderson B.D., Ousdigian K.T. et al. Downloadable software algorithm reduces inappropriate shocks caused by implantable cardioverter-defibrillator lead fractures: a prospective study. Circulation. 2010; 122: 1449-1455.
35. Swerdlow C.D., Sachanandani H., Gunderson B.D. et al. Preventing overdiagnosis of implantable cardioverter-defibrillator lead fractures using device diagnostics. J Am Coll Cardiol. 2011; 57: 2330-2339.
36. Swerdlow C.D., Ellenbogen K.A. Implantable Cardioverter-Defibrillator Leads Design, Diagnostics, and Management. Circulation. 2013; 128: 2062-2071.
37. Tzeis S., Andrikopoulos G., Kolb1 C., Vardas P.E. Tools and strategies for the reduction of inappropriate implantable cardioverter defibrillator shocks. Europace 2008; 10: 1256-1265.
38. Gold M.R., Ahmad S., Browne K. et al. Prospective comparison of discrimination algorithms to prevent inappropriate ICD therapy: Primary results of the Rhythm ID Going Head to Head Trial. Heart Rhythm 2012; 9(3): 370-7.
39. Jack C.M., Hunter E.K., Pringle T.H., et al. An external automatic device to detect ventricular fibrillation. Eur Heart J. 1986 May; 7(5): 404-411.
40. Olson W.H., Bardy G.H., Lund J. et al. Sensing and Detection of Ventricular Fibrillation from Human Epicardial Electrograms for an Implantable Pacer-Cardioverner-Defibrillator. Pacing Clin Electrophysiol. 1988; 11; 486.
41. Kroll M.W., Lehman M.H. Implantable Cardioverter-Defibrillator Therapy. The Engineering-Clinical Interface. Springer Science+Business Media, LLC; NY 1996; 378.
42. Bardy G.H., Troutman C., Poole J.E. Et al. Clinical experience with a tiered-therapy multiprogrammable antiarrhythmia device. Circulation. 1992; 85: 1689-1698.
43. Olson W.H., Peterson D.K., Ruetz L.L. et al. Discrimination of Fast Ventricular Tachycardia From Ventricular Fibrillation and Slow Ventricular Tachycardia for an Implantable Pacer-Cardioverter-Defibrillator Computers in Cardiology 1993; IEEE Computer Society Press 1993: 835-838.
44. Dekker L., Schrama T., Steinmetz F., Tukkie R. Undersensing of VF in a patient with optimal R wave sensing during sinus rhythm. Pacing Clin Electrophysiol. 2004; 27: 833-834.
45. Antolinos-Pérez M.J., Garcia-Alberola A., Redondo-Bermejo B., Valdés-Chavarri M. Failure to Detect Ventricular Fibrillation in a Patient With an Implantable Cardioverter-Defibrillator. Rev Esp Cardiol. 2006; 59(5): 515-518.
46. Гурвич Н.Л. Основные принципы дефибрилляции сердца. - М.: Медицина, 1975. - 231 с.
47. Wilkoff B.L., Fauchier L., Stiles M.K. et al. 2015 HRS/ EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing. Heart Rhythm 2016; 13(2): e50-e86.
48. Tan V.H., Wilton S.B., Kuriachan V. et al. Impact of Programming Strategies Aimed at Reducing Nonessential Implantable Cardioverter Defibrillator Therapies on Mortality: A Systematic Review and Meta-Analysis. Circulation: Arrhythmia and Electrophysiology. February 1, 2014 2014; 7(1): 164-170.
49. Wilkoff B.L., Ousdigian K.T., Sterns L.D. et al. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J. Am. Coll. Cardiol. Jul 18 2006; 48(2): 330-339.
50. Wathen M.S., DeGroot P.J., Sweeney M.O., et al, for the PainFREE Rx II Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. October 26, 2004; 110(17): 2591-2596.
51. Arias M.A., Puchol A., Castellanos E., Rodriguez-Padial L. Anti-tachycardia pacing for ventricular tachycardia: good even after being bad. Europace 2007; 9: 1062-1063.
52. Schoels W., Steinhaus D., Johnson W.B. et al. Optimizing implantable cardioverter-defibrillator treatment of rapid ventricular tachycardia: Antitachycardia pacing therapy during charging. Heart Rhythm 2007; 4: 879-885.
53. Koneru J.N., Swerdlow C.D., Wood M.A., Ellenbogen K.A. Minimizing Inappropriate or “Unnecessary” Implantable Cardioverter-Defibrillator Shocks Appropriate Programming. Circ. Arrhythm. Electrophysiol. 2011; 4: 778-790.
54. Swerdlow C.D., Gunderson B.D., Ousdigian K.T., et al. Downloadable algorithm to reduce inappropriate shocks caused by fractures of implantable cardioverter-defibrilla-tor leads. Circulation. 2008; 118: 2122-2129.
55. Wilkoff B.L., Williamson B.D., Stern R.S. et al. Strategic Programming of Detection and Therapy Parameters in Implantable Cardioverter-Defibrillators Reduces Shocks in Primary Prevention Patients Results From the PREPARE (Primary Prevention Parameters Evaluation) Study (J Am Coll Cardiol 2008; 52: 541-550.
56. Moss A.J., Schuger C., Beck C.A. et al. Reduction in Inappropriate Therapy and Mortality through ICD Programming. MADIT-RIT Trial Investigators. N Engl J Med 2012; 367: 2275-2283.
57. Gasparini M., Proclemer A., Klersy C. et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA. 2013 May 8; 309(18): 1903-11.
58. Auricchio A., Schloss E.J., Kurita T., et al. Low inappropriate shock rates in patients with single and dual/triple chamber ICDs using a novel suite of detection algorithms: PainFree SST Trial Primary Results. Heart Rhythm 2015; 12: 926-936
Рецензия
Для цитирования:
Ревишвили А.Ш., Неминущий Н.М. ТЕРАПИЯ ИМПЛАНТИРУЕМЫХ КАРДИОВЕРТЕРОВ-ДЕФИБРИЛЛЯТОРОВ НА СОВРЕМЕННОМ ЭТАПЕ: СОВЕРШЕНСТВОВАНИЕ И СТАНДАРТИЗАЦИЯ МЕТОДА. Вестник аритмологии. 2017;(87):33-41.
For citation:
Revishvili A.Sh., Neminushchy N.M. CURRENT IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR THERAPY: PROGRESS AND STANDARDIZATION. Journal of Arrhythmology. 2017;(87):33-41. (In Russ.)
Просмотров:
179
Послать статью по эл. почте 